Psoriasis Clinical Trial
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
Candidate for phototherapy or systemic treatment for plaque psoriasis
Need to meet criteria: Total body surface area (BSA) greater than or equal to (>=)1 percent (%) at screening and baseline, and investigator global assessment (IGA) (overall) >=2 at screening and baseline and at least one of the following: scalp-specific investigator global assessment (ss-IGA) score >=3 at screening and baseline, and/or static physician's global assessment of genitalia (sPGA-G) >=3 at screening and baseline, and/or physician's global assessment of hands and feet (hf-PGA) score >=3 at screening and baseline
Failed to respond to at least 1 topical therapy (example, corticosteroids, calcineurin inhibitors, and/or vitamin D analogs) used for treatment of psoriasis
Confirmation of plaque psoriasis in a non-special area (example, areas excluding scalp, genital, palmoplantar) at screening and baseline
Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantar pustulosis of the palmoplantar area (if hf-PGA >=3 at baseline)
Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Fort Smith Arkansas, 72916, United States
Alpharetta Georgia, 30022, United States
Rolling Meadows Illinois, 60008, United States
Plainfield Indiana, 46168, United States
Lake Charles Louisiana, 70605, United States
Fort Gratiot Michigan, 48059, United States
New Brighton Minnesota, 55112, United States
Saint Joseph Missouri, 64506, United States
Omaha Nebraska, 68144, United States
East Windsor New Jersey, 08520, United States
Boardman Ohio, 44512, United States
Portland Oregon, 97210, United States
Arlington Texas, 76011, United States
Pflugerville Texas, 78660, United States
San Antonio Texas, 78213, United States
Mill Creek Washington, 98012, United States
Taipei , 10048, Taiwan
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.